Note: This company is no longer actively listed. Financial data shown is historical.
Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
GlaxoSmithkline Consumer Healthcare Ltd.'s net profit margin of 20.6% in FY2019 reflects excellent profitability, with operating margin at 22.6% and gross margin at 70.0%.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd. posted a gross margin of 70.0%, an operating margin of 22.6%, a net margin of 20.6%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
GlaxoSmithkline Consumer Healthcare Ltd.'s revenue grew 9.3% to 47.82B and net profit grew 40.4% to 9.83B YoY in FY2019, indicating moderate business momentum.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd.'s revenue grew by 9.3% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
GlaxoSmithkline Consumer Healthcare Ltd.'s ROE of 24.0% in FY2019 indicates excellent capital efficiency.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd. reported an ROE of 24.0%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
GlaxoSmithkline Consumer Healthcare Ltd.'s FCF/NI ratio of 0.65x in FY2019 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
GlaxoSmithkline Consumer Healthcare Ltd.'s OCF/NI ratio of 0.68x in FY2019 indicates cash conversion lagging profits — possible working capital challenges.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd.'s operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
GlaxoSmithkline Consumer Healthcare Ltd.'s current ratio of 2.90x in FY2019 indicates healthy short-term liquidity.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd. reported a current ratio of 2.90. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
GlaxoSmithkline Consumer Healthcare Ltd.'s interest coverage ratio of 1,387.5x in FY2019 indicates comfortable debt servicing capacity.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd. reported an interest coverage ratio of 1,387.5x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
GlaxoSmithkline Consumer Healthcare Ltd.'s diluted shares remained virtually unchanged in FY2019.
Over 2 years (FY2018–FY2019), diluted shares remained essentially unchanged at 42.06M.
In FY 2019, GlaxoSmithkline Consumer Healthcare Ltd.'s diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2019